Plus Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTV research report →
About the company
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children.
- CEO
- Marc H. Hedrick
- IPO
- 2001
- Employees
- 21
- HQ
- Austin, TX, US
Price Chart
- Market Cap
- $9.63M
- P/E
- -0.01
- P/S
- 1.86
- P/B
- 2.21
- EV/EBITDA
- -0.89
- Div Yield
- 0.00%
- Gross Margin
- 92.80%
- Op Margin
- -364.36%
- Net Margin
- -230.24%
- ROE
- -198.48%
- ROIC
- -148.83%
- Revenue
- $5.21M · -10.49%
- Net Income
- $-22,386,000 · -72.49%
- EPS
- $-7.19 · 85.25%
- Op Income
- $-15,298,000
- FCF YoY
- -94.79%
- 52W High
- $23.50
- 52W Low
- $2.90
- 50D MA
- $5.55
- 200D MA
- $9.57
- Beta
- 1.37
- Avg Volume
- 303.86K
Get TickerSpark's AI analysis on PSTV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | ANDREWS RONALD ASBURY | other | 922 |
| Jul 1, 26 | Guse Kyle | other | 922 |
| Jul 1, 26 | ANDREWS RONALD ASBURY | other | 922 |
| Jul 1, 26 | Guse Kyle | other | 922 |
| Jul 1, 26 | van Es-Johansson An | other | 922 |
| Jul 1, 26 | van Es-Johansson An | other | 922 |
| Jul 1, 26 | HEDRICK MARC H | other | 6,387 |
| Jul 1, 26 | HEDRICK MARC H | other | 8,066 |
| Jul 1, 26 | HEDRICK MARC H | other | 1,986 |
| Jul 1, 26 | HEDRICK MARC H | other | 1,986 |
Our PSTV coverage
Recent articles, reports, and earnings notes.
No research on PSTV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSTV report →Similar companies
Peers in the same neighborhood.